Preclinical and clinical evaluations of GPIIb/IIIa receptor antagonists rely heavily on the relationship between ex vivo platelet inhibition assays, and in vivo antithrombotic ef~cacy. The ex vivo platelet aggregation assay utilizes trisodium citrate as the conventional anticoagulant for the collection of whole blood to be used for the preparation of platelet-rich plasma (PRP). Unfortunately, the reduction or removal of the ionized calcium concentration from the PRP by trisodium citrate induces a morphological change in the platelets [1] and in_uences the stability of the GPIIb/IIIa complex [2-4] and the divalent cation-dependent binding of RGD ligands to the GPIIb/IIIa receptor [5, 6] . Under such circumstances, the ex vivo platelet aggreagation studies may falsely reveal a greater antiplatelet potency of a particular antagonist of the glycoprotein receptor.
Preclinical and clinical evaluations of GPIIb/IIIa receptor antagonists rely heavily on the relationship between ex vivo platelet inhibition assays, and in vivo antithrombotic ef~cacy. The ex vivo platelet aggregation assay utilizes trisodium citrate as the conventional anticoagulant for the collection of whole blood to be used for the preparation of platelet-rich plasma (PRP). Unfortunately, the reduction or removal of the ionized calcium concentration from the PRP by trisodium citrate induces a morphological change in the platelets [1] and in_uences the stability of the GPIIb/IIIa complex [2] [3] [4] and the divalent cation-dependent binding of RGD ligands to the GPIIb/IIIa receptor [5, 6] . Under such circumstances, the ex vivo platelet aggreagation studies may falsely reveal a greater antiplatelet potency of a particular antagonist of the glycoprotein receptor.
It is important to note that both intracellular and extracellular calcium play an important role in platelet aggregation. Intracellular calcium in_uences the platelet shape change, exposure of GPIIb/IIIa receptors, and~brinogen binding [7] [8] [9] . On the other hand, control of the extracellular ionized calcium concentration, within the physiologic range (1 m/M), is essential for maintaining the GPIIb/IIIa receptor complex in a conformation capable of interacting with soluble~brino-gen on exposure of the platelet to an agonist. Complexing extracellular ionized calcium ions to the four repetitive domains (resembling calmodulin or troponin C) on the GPIIb subunit of the integrin receptor plays a role in the stability of the receptor complex [10, 11] . In addition to the four calcium-binding sites, there is a proposed~fth site, known as the metal ion-dependent adhesion site (MIDAS) domain, on the GPIIIa [12] [13] [14] . Divalent cations, such as Ca 2ϩ and Mn 2ϩ , can compete with RGD-containing ligands or synthetic antagonists to bind to the activated GPIIb/IIIa receptor [15, 16] . Although trisodium citrate may not alter the intracellular calcium ion concentration, it can certainly do so extracellularly in the platelet suspension, and consequentially alter receptor function. In addition, removal of calcium from the receptor sites may enhance the binding of GPIIb/IIIa antagonists and may, therefore, introduce an artifact in evaluating the in vivo ef~cacy of the antagonists.
We have provided evidence for this phenomenon with TP-9201, a small, peptidomimetic, cyclic GPIIb/IIIa receptor antagonist [17] . In this study two dosing regimens (120 l/kg ϩ 3 l/kg/min and 185 l/kg ϩ 5 l/kg/min) were used, with the expectation of a dose-related effect on platelet inhibition and antithrombotic ef~cacy. However, both the dosing regimens completely inhibited (Ͼ90%) ADP-induced platelet aggregation in citrated PRP (cPRP). In heparinized PRP (hPRP), the low and high doses of TP-9201 produced 21% and 45% inhibition of platelet aggregation, respectively. Dose-dependent prolongation of bleeding time and prevention of thrombosis were also observed. A similar observation has been reported by Collen et al. using TP-9201 [18] . In these studies the GPIIb/IIIa receptor antagonist exhibited enhanced potency based on the ex vivo assay in citrated blood. We aimed to investigate whether chelation of calcium by trisodium citrate was responsible for this phenomenon. Accordingly, the objective of the present investigation was to assess the differential in vitro potencies of structurally different GPIIb/IIIa antagonists under hypocalcemic and normocalcemic conditions. 
Methods

Reagents
Blood collection
After informed consent, blood was collected from healthy, drug-free human volunteers in either trisodium citrate (1:10 citrate to blood;~nal concentration, 0.37%), PPACK (~nal concentration, 20 lg/mL of blood), or heparin (~nal concentration, 10 U/mL).
Platelet aggregation studies
The whole blood cell count was determined with an H-10 cell counter (Texas International Laboratories, Houston, TX). Platelet-rich plasma (PRP) was obtained by centrifuging anticoagulated whole blood at 1000 rpm for 5 minutes (140 g). PPP was prepared after the PRP was removed by centrifuging the remaining blood at 2000 g for 10 minutes and discarding the bottom cellular layer. All centrifugations were done at 21ЊC. The PRP obtained from citrated blood (cPRP) and PPACK-anticoagulated blood (pPRP) was diluted with the respective PPP to achieve a platelet count of 200,000/lL. Ex vivo platelet aggregation was assessed by established spectrophotometric methods with a four-channel aggregometer (BioData-PAP-4, Bio Data Corp., Hatboro, PA) by recording the increase in light transmission through a stirred suspension of PRP (410 lL). Aggregation studies were performed after samples were rewarmed to 37ЊC. Aggregation was induced with ADP (20 lM) or TRAP (SFLLRN-NH2; 10 lM). All antagonists were incubated in PRP for 1 minute, after which the platelet agonists were added. Agonists and antagonists (c7E3, DMP-728, MK-383, and SM-20302) were added in a volume of 50 lL, and the extent of inhibition was examined by light transmittance aggregometry. Values for platelet aggregation were expressed as the percentage of light transmission standardized to PRP and PPP samples yielding 0% and 100% light transmission, respectively. The IC 50 values were determined from a sigmoidal dose-response relationship using GraphPad Prism (Version 2.0a, GraphPad Software, Inc.). A minimum of 8-10 concentrations were used for all antagonists.
To study the effect of calcium chelation on the inhibitory potency of GPIIb/IIIa receptor antagonists, varying concentrations of trisodium citrate were added to pPRP and the aggregatory response of ADP (20 lM) was examined in the presence of a subthreshold concentration of each antagonist.
Concentration of ionized calcium in plasma
Whole blood samples were collected in individual tubes containing either trisodium citrate, PPACK, or heparin as the anticoagulant. The blood samples were processed for the preparation of PPP and PRP as described previously and were analyzed for ionized calcium concentration using an ion analyzer (Nova-6, Nova Biomedical Instruments, Waltham, MA).
Statistical analysis
The data are expressed as the mean Ϯ SEM. An unpaired t-test was used to assess differences in values obtained in cPRP and pPRP. Values were determined to be statistically different at a level of P Ͻ 0.05.
Results
Concentration of ionized calcium in plasma using different anticoagulants
The concentration of ionized calcium was measured in PRP and PPP samples that were anticoagulated initially with either trisodium citrate, PPACK, or heparin ( Table 1 ). The mean ionized calcium concentrations in the PRP prepared from citrate, PPACK, and heparin were 0.056, 1.08, and 0.98 mM, respectively. Similarly, the mean ionized calcium concentrations in the PPP samples prepared from citrate, PPACK, or heparin were 0.059, 1.13, and 0.971 mM, respectively. The concentration of ionized calcium in citrated plasma was 19 times lower than that in heparinized plasma (P Ͻ 0.05) and 16-17 times lower than in PPACK anticoagulated plasma (P Ͻ 0.05).
In vitro potency of GPIIb/IIIa receptor antagonists
The platelet inhibition pro~le in cPRP differed signi~cantly from that in pPRP (Table 2 ). For example, the estimated IC 50 for c7E3 for inhibiting ADP-induced platelet aggregation in cPRP was 1.6 times lower than that in pPRP. Figure 1 is a representative platelet inhibition pro~le of c7E3 (5 lg/mL) in cPRP and pPRP treated with 20 lM ADP. It is evident that 5 lg/mL of c7E3, which is the IC 50 for ADP-induced platelet aggregation in pPRP, produced complete inhibition of the aggregation response in cPRP. The IC 50 values for inhibiting TRAP-induced platelet aggregation were higher, but the difference in cPRP and pPRP was 1.7-fold (P Ͻ 0.05). MK-383, DMP-728, and SM-20302 also demonstrated 1.96-, 1.15-, and 1.43-fold lower IC 50 values, respectively, in cPRP compared with that in pPRP.
Effect of calcium chelation on the platelet inhibitory action of GPIIb/IIIa receptor antagonists
To examine the inhibitory effects of the antagonists in the presence of varying calcium concentrations, trisodium citrate was added to pPRP samples (Figure 2) .
Irrespective of the structure, all the antagonists produced negligeable inhibition when the ionized calcium was 0.9 mM to 1 mM. Further depletion of calcium led to accentuation of the inhibitory response of the subthreshold concentrations of all the antagonists.
Discussion
The discordance between the IC 50 values obtained using trisodium citrate and PPACK can be explained by the varying concentration of ionized calcium in the two assay media. We noted that the ionized calcium concentration in cPRP was 16-19 times less than that in hPRP and pPRP. A physiologic concentration of extracellular ionized calcium is critical to maintain the integrity of the GPIIb/IIIa heterodimer complex on the platelet surface [2, 19] and~brinogen binding to the activated integrin receptor [20] [21] [22] . The concentration of ionized calcium can also in_uence the formation of GPIIb/IIIa heterodimers [23] , and the GPIIb/IIIa and brinogen interaction [5] . Human platelets incubated with the extracellular calcium chelators, EDTA and EGTA, undergo morphological changes [1] and fail to aggregate [2, 3, 24] , or bind to~brinogen in response to ADP [9, 20, 22] . Winters et al. [25] demonstrated that the binding of MoAb 10E5, a complex speci~c antiGPIIb/IIIa antibody, to the platelets was reduced by 80% under the conditions of complete absence of calcium and a temperature of 37ЊC. The extent to which the platelet response is altered depends on the degree of calcium chelation. Trisodium citrate is not as effective as EDTA in chelating extracellular calcium, but it does induce hypocalcemic conditions as indicated by our data. In the present study, the presence of a GPIIb/IIIa receptor antagonist in cPRP may have acted in concert with low Ca ϩ2 concentration to reduce the platelet aggregation response, thereby yielding a false indication of the drug's in vivo potency in terms of preventing platelet aggregation.
Investigation of the current literature on the preclinical evaluation of GPIIb/IIIa receptor antagonists indicates that trisodium citrate was the anticoagulant used to collect blood for ex vivo platelet inhibition studies, and as a result there was discordance between the ex vivo platelet inhibition data and the in vivo ef~cacy data. For example, using c7E3 in a primate model of carotid artery thrombosis, it was shown that the 0.15 mg/kg and 0.25 mg/kg doses had a similar ex vivo platelet inhibition pro~le (80-90%), but the incidence of occlusion was 66% and 0% for the low and high doses, respectively [26] . Lynch et al. [27] observed that a 3 lg/kg/min and 10 lg/kg/min infusion of MK-383 was associated with a 90-100% and 100% inhibition of collagen-induced platelet aggregation. However, in a canine model of primary coronary artery thrombosis, only the 10 lg/kg/min regimen was effective. Similarly, the 0.1 and 1.0 mg/kg doses of DMP-728 produced 75-100% and 90-100% inhibition of ADP-induced platelet aggregation in cPRP, and the incidences of carotid artery occlusion occlusion were 17% and 0% respectively. The lack of correlation between platelet inhibition in cPRP and the in vivo antithrombotic ef~cacy was also evident in previous studies employing L-738, 167 [28] , SC-49992 [29] , TP-9201 [17] , and SM-20302 [30] . These studies reinforce the concept that platelet aggregation performed in cPRP is a poor indicator of the in vivo activity of GPIIb/IIIa receptor antagonists. Our in vitro data with GPIIb/IIIa receptor antagonists may help to provide a better understanding of the outcome of the integrilin trials. Using four different dosing strategies of integrilin (Epti~batide) in patients scheduled for elective percutaneous interventions, it was observed that administration of a bolus (90-180 lg/kg) followed by an infusion (0.5-1 lg/kg/min for 20 hours) did not result in a dose-related inhibition of ADP-induced platelet aggregation in cPRP. The maximum inhibition produced by all four dosing regimens was 90% [31] . In the IMPACT-II study [32] it was noted that despite 70-78% inhibition of ADP-induced platelet aggregation in cPRP, integrilin treatment did not in_uence 6-month clinical outcomes after PTCA. Recently Phillips et al. [33] provided evidence for the integrilin discrepancy by demonstrating that the IC 50 values for ADP and TRAP-induced platelet aggregation in cPRP were 4-and 7.5-fold lower than those in pPRP. Furthermore, these investigators made use of PAC1, an antibody having binding properties that mimic the binding of~brinogen to GPIIb/IIIa. PAC1, like~brinogen, has similar divalent cation requirements for binding, requires platelet activation before binding can occur, and its binding can be affected by inhibitors of GPIIb/IIIa. The concentration of integrilin required to inhibit PAC1 binding in cPRP was lower than that required in pPRP, indicating that enhanced inhibition by integrilin in cPRP was the result of enhanced inhibition of ~brinogen binding. The pharmacodynamic determinations of the platelet aggregation inhibitory activity of integrilin, therefore, is enhanced by collection of blood samples with citrate as the anticoagulant [33] . The integrilin trials indicate that an effective dosing regimen for in vivo inhibition of platelet reactivity may correlate with less than 80% inhibition of ex vivo platelet aggregation responses to ADP and/or TRAP. Later the PURSUIT trials revealed that a modi~ed and clinically effective dosing regimen, guided by ex vivo aggregation studies done in PPACK-PRP, and which did not inhibit completely the platelet aggregation response, could be used with relative safety. In contrast to integrilin, the differences in the IC 50 values between cPRP and pPRP in our study were smaller (about two fold for MK-383). This may be due to the extent of calcium chelation in the two studies. We used 0.37% of trisodium citrate, whereas Phillips et al. used 0.57%.
In conclusion, using several structurally unrelated inhibitors of the platelet GPIIb/IIIa receptor, our observations, which are in agreement with those of Phillips et al. [33] , suggest that the decrease in ionized calcium ion concentration renders the platelets more susceptible to inhibition by GPIIb/IIIa antagonists when challenged with platelet agonists. The use of PPACK, heparin, or hirudin as an anticoagulant during the collection of the blood sample maintains the ionized calcium concentration similar to that in the in vivo situation. The latter approach may provide a more accurate ex vivo assessment of platelet reactivity in response to aggregating agents, and may be more suited to the mechanistic study of platelet function, where it becomes essential to correlate the ex vivo observation with an anticipated in vivo effect, that is, prevention of arterial thrombosis. The use of a proper anticoagulant should result in a better correlation between the ex vivo and in vivo~ndings, and assist in maintaining an optimal dosing regimen while avoiding or reducing the incidence of untoward effects related to hemostasis.
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